Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity.
Bakheit
A M O
AM
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D020521:Stroke / Q000150:complications*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A